Breathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improve walking after spinal cord injury (SCI). The greatest improvements in walking ability occur when LOT is administered prior to skill-based walking practice (WALK). However, the enduring benefits of LOT on walking recovery may be undermined by the accumulation of LOT-induced increase in extracellular adenosine. The goal of the study is to understand the extent to which istradefylline (adenosine 2a receptor antagonist) may limit the competing mechanisms of adenosine on LOT-induced walking recovery following SCI.

Start Date01 Sep 2027

Sponsor / Collaborator

The Spaulding Rehabilitation Hospital Corp.

NCT07704385

/ Not yet recruitingPhase 1/2IIT

Enhancing Rehabilitation in Aging Study (ERAS)

Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.

Start Date01 Oct 2026

Sponsor / Collaborator

University of Florida

JPRN-jRCTs051250026

/ RecruitingPhase 2

Clinical trial on the efficacy and safety of istradefylline as an adjunctive therapy for obsessive-compulsive disorder

Start Date19 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Istradefylline

100 Translational Medicine associated with Istradefylline

100 Patents (Medical) associated with Istradefylline

410

Literatures (Medical) associated with Istradefylline

01 Oct 2026·NEUROPHARMACOLOGY

The adenosine A2A receptor antagonist KW6002 mitigates aldosterone-induced central serous chorioretinopathy in mice

Article

Author: Yang, Jiasheng ; Xu, Kailang ; Tang, Wei-Hang ; Liu, Qiaoli ; Yu, Zijun ; Li, Jiaqi ; Chen, Jiang-Fan ; Qu, Jia ; Que, Jia-Nan

PURPOSE:

Central serous chorioretinopathy (CSC), a prevalent disease characterized by choroidal vascular abnormalities, has extremely limited treatment options. This study investigates the effects of the selective adenosine A_2A receptor (A_2AR) antagonist KW6002 on choroidal vascular hyperpermeability and the blood-retinal barrier (BRB), and explores its therapeutic potential in experimental CSC.

METHODS:

We examined A_2AR expression in the retinal pigment epithelium (RPE)-choroid-sclera complex using quantitative real-time PCR (qPCR) and Western blotting (WB) in mice with an established aldosterone-induced acute CSC model. Before modeling and after model establishment, mice were administered 5 mg/kg KW6002 or a vehicle control via intraperitoneal injection. The retinal and choroidal thickness was assessed by optical coherence tomography (OCT) and hematoxylin-eosin (H&E) staining. We observed Müller cells activation, retinal microglia infiltration, and proinflammatory cytokine expression via immunofluorescence and qPCR. Next, we employed the effects of the A_2AR antagonist KW6002 and genetic A_2AR knockout (A_2AR-KO) on BRB integrity using immunofluorescence and WB. Finally, to clarify how A_2AR knockout confers therapeutic benefits in CSC, we assessed activation of the TNF-α/NF-κB-MMP-2/9 signaling pathway.

RESULTS:

We found that A_2AR signaling was significantly upregulated in the RPE-choroid-sclera complex in CSC models, and both A_2AR antagonist KW6002 and A_2AR-KO significantly inhibited the aldosterone-induced central retinal and choroidal pathologic thickening. Moreover, the KW6002 intervention decreased the activation of Müller cells and the proliferation of microglia, inhibited the secretion of proinflammatory cytokines (TNF-α, IL-6, and IL-1β), and ameliorated the retinal damage caused by aldosterone; in contrast, A_2AR-KO resulted in significant upregulation of key tight junction proteins (ZO-1, Claudin-1, and Claudin-5). In summary, these results suggest that the protective effects may be correlated with the suppression of the TNF-α/NF-κB-MMP-2/9 signaling axis.

CONCLUSIONS:

Our findings show that the A_2AR antagonist KW6002 or A_2AR-KO offers a protective effect in experimental CSC, reduces inflammation, and maintains the integrity of the BRB, which may be associated with the inhibition of the TNF-α/NF-κB-MMP-2/9 pathway. These findings present a new method for preventing and treating CSC, which will guide our future clinical strategy development.

01 Jun 2026·Purinergic Signalling

Purinergic modulation in Parkinson’s disease: the dual role of istradefylline in motor and cognitive outcomes

Review

Author: Rejili, Mokhtar ; Shokr, Mustafa M ; Al-Gareeb, Ali I ; Al-Kuraishy, Hayder M ; Jabir, Majid S ; Albuhadily, Ali K ; Batiha, Gaber El-Saber

Istradefylline, a selective adenosine 2A receptor (A2AR) antagonist, was approved in 2019 as an adjuvant treatment to reduce "OFF" periods in Parkinson's disease (PD) patients. This comprehensive review evaluates its dual impact on PD, contrasting established therapeutic benefits in motor symptom management with emerging concerns regarding cognitive safety. Istradefylline enhances dopaminergic transmission in the substantia nigra pars compacta (SNpc), significantly reducing L-DOPA-induced akinesia. Beyond motor control, it exhibits neuroprotective potential by mitigating neuroinflammation, oxidative stress, and alpha-synuclein-induced neurotoxicity. However, preclinical evidence suggests a concerning paradox: istradefylline may exacerbate cognitive decline by promoting amyloid-beta (Aβ) accumulation through the overactivity of γ-secretase and the disruption of brain-derived neurotrophic factor (BDNF) signaling pathways. Furthermore, its inhibitory effect on D-aspartate protein may trigger mitochondrial dysfunction and endoplasmic reticulum stress, potentially accelerating neurodegeneration in the SNpc. While istradefylline remains a valuable non-dopaminergic strategy for stabilizing motor fluctuations, its influence on long-term cognitive function necessitates careful clinical consideration. Understanding the molecular mechanisms behind these opposing effects is essential for optimizing its use and minimizing neurocognitive risks in PD patients. Future longitudinal trials are vital to clarify its long-term safety profile and disease-modifying potential.

01 Jun 2026·TISSUE & CELL

Adenosine A₂A receptor as a dual-acting molecular switch: Glial morphological changes and neurovascular tissue remodeling in neuroinflammation and neurodegeneration

Review

Author: Khalifa, Heba S ; Ali, Mohamed A M ; Elnaghy, Fatma ; El-Moaty, Heba Ibrahim Abd ; Sameh, Ahmed ; Elmorsy, Elsayed A ; Ibrahim, Essam H ; Hasan, Waseem Ali ; Hamad, Rabab S ; Morsy, Kareem ; AlShehri, Mohammed A ; Gaafar, Ahmed ; El-Kott, Attalla F ; Saber, Sameh ; Farrag, Alshaimaa A ; Alsoqih, Norah Suliman ; Negm, Sally ; Eissa, Hanan

Neuroinflammation appears in a variety of neurological disorders, including multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis. The adenosine A₂A receptor (A₂AR), a Gs protein-coupled receptor that affects cAMP signaling and downstream kinases like PKA, CREB, and NF-κB, is one of the primary regulators of this process. Context-dependent effects of A₂AR activation include lowering acute inflammation and promoting neuronal survival when stimulated moderately, but increasing glial activation and cytokine production when overexpressed over an extended period of time. In microglia and astrocytes, A₂AR signaling regulates inflammatory pathways mediated by NF-κB and MAPK, affecting oxidative stress, blood-brain barrier (BBB) stability, and excitotoxicity. Acute or transient (short-term) A₂AR activation, on the other hand, increases the production of anti-inflammatory cytokines like IL-10 and enhances neurotrophic support through BDNF. A₂AR antagonists, including istradefylline and SCH58261, may reduce microglial triggering and have neuroprotective benefits, according to clinical and experimental data. The context-dependent activity of the receptor is shown by the fact that total receptor blockage interferes with adaptive immune control. Therefore, the therapeutic challenge is to carefully modify A₂AR signaling in particular cell populations, specifically targeting astrocytic or microglial receptors while maintaining the peripheral immunoregulatory activities. The dual regulatory role of A₂AR in neuroinflammation is summarized in this review along with its molecular mechanisms, disease-specific actions, and therapeutic significance. Developing next-generation neuroprotective strategies that reduce A₂AR signaling's pro-inflammatory and neurotoxic effects while preserving its beneficial homeostatic effects will require an understanding of the temporal and cell-specific dynamics of this signaling.

News (Medical) associated with Istradefylline

26 Jun 2026

·www.biospace.com

New Autism Research to be Presented at European Purine Scientific Meeting

CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3 rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor. Dr. Becker’s presentation, “Adenosine A2A Receptors as a Therapeutic Target in Autism Spectrum Disorders”, will be given next Friday. The presentation will highlight the pivotal role that Adenosine A2a receptors (A2ARs) play in the neural reward circuits involved in social interaction and communication. Research shows that A2AR antagonism consistently improves social interaction across multiple preclinical models displaying autism-like phenotypes, suggesting that drugs that target the A2AR are a very promising therapeutic target to alleviate social deficits associated with autism spectrum disorders. Marvel and Dr. Becker and Dr. Julie Le Merrer’s research team at the iBraiN institute have collaborated for the past three years to advance the scientific understanding of A2AR biology and evaluate the therapeutic potential of MB-204, Marvel's lead A2AR antagonist, in multiple preclinical models of autism (e.g., Oprm1 , Mecp2 , Shank3 – data forthcoming). "Dr. Becker is a world-class researcher whose work has been instrumental in advancing the understanding of adenosine A2A receptors in autism," said Rod Matheson, Chief Executive Officer of Marvel Biosciences. "Over the past three years, our collaboration has generated compelling preclinical data demonstrating the potential of MB-204 across multiple validated models of autism. Marvel Biosciences is proud to support the European Purine Meeting, and we hope this will raise greater awareness of this field of research in autism. " The Company is also pleased to share its recent interview with Radius Research, featuring Chief Executive Officer, Rod Matheson, and Chief Science Officer, Mark Williams. The interview shares insight into Marvel's patented lead asset, MB-204, the Company's development roadmap, upcoming milestones, and the opportunities ahead as Marvel advances toward Phase 1 clinical studies. Link to interview: About Marvel Biosciences Corp. Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson’s drug and the only adenosine A2A receptor blocker currently on the market. Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer’s disease. Marvel is also exploring MB-204’s potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments. Contact Information: Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer Email: rod@marvelbiosciences.com Dr. Mark Williams, President and Chief Science Officer Email: mark@marvelbiosciences.com Tel: 403 770 2469 Website: | Twitter/X | LinkedIn Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is deﬁned in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and oﬃcers have relied on each other for any information concerning such Party. This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identiﬁed by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could diﬀer materially from those anticipated in such statements. Important factors that could cause actual results to diﬀer materially from the expectations of the Company and include other risks detailed from time to time in the ﬁlings made by the Company under securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to diﬀer materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may diﬀer materially from those anticipated. Forward-looking statements contained in this news release are expressly qualiﬁed by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

08 Jun 2026

·www.biospace.com

Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026. The patent is expected to be granted shortly after August 28, 2026. The Australian notice of allowance further strengthens Marvel's global composition-of-matter patent portfolio for MB-204, reinforcing the Company's intellectual property position as it advances into Phase I clinical development following positive preclinical efficacy and toxicology results. Such includes recent preclinical studies in Rett syndrome models that demonstrated that MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints and produced sustained therapeutic benefits that persisted after treatment cessation, suggesting the potential for disease-modifying effects. Broadening patent protection across key pharmaceutical markets enhances the asset's commercial value by extending market exclusivity, reducing competitive risk, and increasing its attractiveness for potential licensing, partnering, and strategic investment opportunities. “We are continuing to extend our composition of matter patent protection of MB-204 to all major markets”, commented Marvel CEO Rod Matheson “and we continue to look forward to receiving similar rulings for the other jurisdictions. We have also recently filed for patents on a novel liquid-based formulation of MB-204 which should help lengthen the lifetime of our patent estate.” MB-204 is a novel fluorinated analogue of the approved adenosine A2a receptor antagonist Istradefylline which is used for the treatment of Parkinson’s Disease. MB-204 has demonstrated superior pharmacokinetics and completed pre-clinical toxicology testing and has shown excellent pre-clinical efficacy studies in depression and multiple models of autism including Rett Syndrome. The compound is currently being tested in Fragile X models. Currently, around 1 in 36 children at age 8 have been diagnosed with autism spectrum disorder which underscores the urgency for new agents. The patent advancement follows a series of significant achievements in 2026, including the granting of U.S. and Japanese composition-of-matter patents for MB-204, the selection of Novotech as the Company's contract research organization for its planned Phase I clinical trial, the securing of non-dilutive funding support from Alberta Innovates, strategic investment participation from 5 Horizons Ventures, and the development of novel pediatric-friendly liquid formulations that may further expand the Company's intellectual property estate. Collectively, these achievements continue to validate Marvel's scientific platform, strengthen its credibility within the biotechnology sector, and support the Company's transition from a pre-clinical organization to a clinical-stage drug development company. About Marvel Biosciences Corp. Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson’s drug and the only adenosine A2A receptor blocker currently on the market. Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer’s disease. Marvel is also exploring MB-204’s potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments. Contact Information: Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer Email: rod@marvelbiosciences.com Dr. Mark Williams, President and Chief Science Officer Email: mark@marvelbiosciences.com Tel: 403 770 2469 Website: | Twitter/X | LinkedIn Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is deﬁned in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and oﬃcers have relied on each other for any information concerning such Party. This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identiﬁed by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could diﬀer materially from those anticipated in such statements. Important factors that could cause actual results to diﬀer materially from the expectations of the Company and include other risks detailed from time to time in the ﬁlings made by the Company under securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to diﬀer materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may diﬀer materially from those anticipated. Forward-looking statements contained in this news release are expressly qualiﬁed by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Phase 1

20 May 2026

·www.biospace.com

Marvel Biosciences Announces Grant of Deferred Share Units

Calgary, Alberta--(News - May 20, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), announces the award of 50,001 deferred share units (" DSUs ") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on May 19, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days after such directors' separation from service. The deemed value for the DSUs is calculated using the VWAP of the Corporation's Common Shares on the TSX Venture Exchange on May 19, 2026 being $0.15 multiplied by the number of DSUs awarded. About Marvel Biosciences Corp. Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel ﬂuorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A signiﬁcant and growing body of scientiﬁc evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach. Contact Information: Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer or Dr. Mark Williams, President and Chief Science Officer Tel: 403 770 2469 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is deﬁned in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and oﬃcers have relied on each other for any information concerning such Party. This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identiﬁed by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could diﬀer materially from those anticipated in such statements. Important factors that could cause actual results to diﬀer materially from the expectations of the Company and include other risks detailed from time to time in the ﬁlings made by the Company under securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to diﬀer materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may diﬀer materially from those anticipated. Forward-looking statements contained in this news release are expressly qualiﬁed by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law. To view the source version of this press release, please visit

Drug Approval

100 Deals associated with Istradefylline

External Link

KEGG	Wiki	ATC	Drug Bank
D04641	Istradefylline	N04B	DB11757

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	Japan	Kyowa Kirin Co., Ltd.	25 Mar 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Parkinson's disease	Phase 3	China	CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.	28 Feb 2019
Mild cognitive disorder	Phase 2	United States	Kyowa Kirin, Inc.	18 Jul 2022
Restless Legs Syndrome	Phase 2	United States	Kyowa Kirin, Inc.	01 Jul 2005
Drug abuse	Phase 1	United States	Kyowa Kirin Co., Ltd.	01 Jan 2016
Cachexia	Phase 1	United States	Piston Bio LLC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MDS2024	Not Applicable	Parkinson Disease	2,045	Istradefylline 40 mg	zjdeyhnwdp(bnvxveapyd) = dmtrhkznpo grwnxjourd (zmcwvkjdqz, 90 - 365) View more	Positive	27 Sep 2024
				Istradefylline 40 mg (Medicare replacement)	zjdeyhnwdp(bnvxveapyd) = ahcppdwhhy grwnxjourd (zmcwvkjdqz, 90 - 365) View more
P5-3.017 (AAN2024)	Not Applicable	Parkinson Disease	-	Istradefylline 40mg	vcirsbseui(eglqupsdwt) = The odds of hallucinations were significantly higher for amantadine vs. istradefylline at 40 and 20mg iokpxjtygt (sbkpcwsevn ) View more	Positive	09 Apr 2024
				Istradefylline 20mg
MDS2023	Phase 3	-	214	Istradefylline	svvlogtgvq(khgqzdctup) = pbchudbunw lbsdbpwfuk (hfxapczzsb )	Positive	27 Aug 2023
				No Istradefylline	svvlogtgvq(khgqzdctup) = hpllmyzafm lbsdbpwfuk (hfxapczzsb )
AAN2022	Not Applicable	Parkinson Disease	-	Istradefylline 20 mg	dlyadccdvr(zzzqgvstgn) = jggjnabdat iispoadjjd (ufwlnttnfc ) View more	Positive	03 May 2022
				Istradefylline 40 mg	ixufwyeoud(isburylbmn) = mpdpgbpcoe uygumneqsq (bohwdlzrkn )
NCT01968031 (KW-6002, CTgov)	Phase 3	Parkinson Disease	613	Placebo (Placebo)	vvalikrpci(hkgrimurbq) = aoizstosgo himvhikcst (uewujoqppn, tqritjvvjb - ojcwguusoy) View more	-	20 Nov 2020
				Placebo+Istradefylline 20 mg (Istradefylline 20 mg/Day)	vvalikrpci(hkgrimurbq) = wcuzesylyi himvhikcst (uewujoqppn, ijpceyelyo - rkthnqbwpn) View more
pooled analysis of four pivotal randomized controlled trials of istradefylline (ANA2020)	Phase 3	Parkinson Disease	1,143	Istradefylline 20mg/day	slhezdomsk(fbhpojfjjx) = yfohecrcez cxkshgmphb (vjcaytbmgx, -1.10 to -0.40) View more	Positive	25 Sep 2020
				Istradefylline 40mg/day	slhezdomsk(fbhpojfjjx) = dqvgicjnoi cxkshgmphb (vjcaytbmgx, -1.17 to -0.47) View more
ANA2020	Phase 2/3	-	1,160	Istradefylline 20 mg/day	htvmyyiiad(qkjmgscrzc) = The most common TEAE was dyskinesia (20 mg/day, 14.6%; 40 mg/day, 16.7%; placebo, 7.5%) zgplhyrrtg (kyneugkbun ) View more	Positive	25 Sep 2020
				Istradefylline 40 mg/day
MDS2020	Not Applicable	-	31	Istradefylline 20 mg/day	trntnlccyn(mcfpjsbglf) = 2 (6.5%) patients btvhexzida (zrmflxooxv ) View more	-	12 Sep 2020
				Placebo
MDS2020	Phase 2/3	Parkinson Disease	1,143	Istradefylline 20mg/day	lrribxqgbc(cijffwgigx) = Dyskinesia was the most frequent adverse event (20mg, 15%; 40mg, 17%; placebo, 8%) gtlslrgdah (kstvfydqby )	Positive	12 Sep 2020
EAN2020	Not Applicable	Parkinson Disease	-	Istradefylline 40mg/day	uequghnmec(xqscqmqfod) = Among TEAEs (frequency â¥5%), nasopharyngitis, dyskinesia, contusion, and constipation became more frequent with dose increase vs maintaining 20mg/day lxacmxquzm (hrtwzlofcr )	-	22 May 2020
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis